Reproductive Sciences

Setting New Year's Health Resolutions? OB-GYN Offers Guidance on Prioritizing Women’s Sexual and Reproductive Well-Being in 2024

Retrieved on: 
Tuesday, January 16, 2024

, OB-GYN, Clinical Professor of Obstetrics, Gynecology and Reproductive Sciences at the Yale University School of Medicine, offers insights into the common questions women might have as they set health goals for 2024.

Key Points: 
  • , OB-GYN, Clinical Professor of Obstetrics, Gynecology and Reproductive Sciences at the Yale University School of Medicine, offers insights into the common questions women might have as they set health goals for 2024.
  • A balanced diet is crucial for overall health, including female sexual health.
  • Regular checkups with your health care provider can help address any concerns related to sexual health.
  • “As we settle into 2024, it’s important to remember that individual health needs vary," adds Dr. Minkin.

World-Renowned Surgeon Joins NYU Langone Health as Division Director of Minimally Invasive and Specialty Gynecologic Surgery

Retrieved on: 
Wednesday, January 3, 2024

NEW YORK, Jan. 3, 2024 /PRNewswire/ -- A leading gynecologic surgeon, Ted T. Lee, MD , has joined NYU Langone Health as director of the Division of Minimally Invasive and Specialty Gynecologic Surgery and chief of surgical innovation for gynecology in NYU Grossman School of Medicine's Department of Obstetrics and Gynecology , effective January 1.

Key Points: 
  • NEW YORK, Jan. 3, 2024 /PRNewswire/ -- A leading gynecologic surgeon, Ted T. Lee, MD , has joined NYU Langone Health as director of the Division of Minimally Invasive and Specialty Gynecologic Surgery and chief of surgical innovation for gynecology in NYU Grossman School of Medicine's Department of Obstetrics and Gynecology , effective January 1.
  • In his new roles, Dr. Lee will oversee minimally invasive surgical services that treat common and complex gynecologic conditions at NYU Langone's Manhattan campus and NYU Langone Hospital—Brooklyn.
  • "I am dedicated to advancing the boundaries of minimally invasive gynecologic surgery, ensuring world-class, patient-centered care," said Dr. Lee.
  • "This is an exciting chapter and I look forward to contributing to the continued excellence in women's health care at NYU Langone."

Harvard Apparatus Regenerative Technology and Renowned Professor/Physician Establish a Collaboration to Repair and Regenerate the Uterus

Retrieved on: 
Monday, December 4, 2023

The program will focus on the use of Harvard Apparatus Regenerative Technology’s cell-based scaffold platform to restore fertility by repairing uterine tissue in a mouse model of uterine damage.

Key Points: 
  • The program will focus on the use of Harvard Apparatus Regenerative Technology’s cell-based scaffold platform to restore fertility by repairing uterine tissue in a mouse model of uterine damage.
  • Any event that causes damage to the endometrium may lead to the development of IUAs, resulting in menstrual disturbances, infertility and (recurrent) pregnancy loss.
  • IUAs have a debilitating impact on the health and quality of life in women of childbearing age while the economic burden is substantial.
  • This will be a unique opportunity to test our technology in a hollow organ outside the gastrointestinal tract,” commented William Fodor, PhD, Chief Scientific Officer.

Mirvie Announces Completion of Enrollment of 10,000 Person Landmark Research Study for Pregnancy Health

Retrieved on: 
Tuesday, November 14, 2023

Mirvie , a company pioneering the prediction of life-threatening pregnancy complications months in advance, today announced the completion of enrollment of its landmark 10,000 person research study for pregnancy health, in collaboration with leading experts in obstetrics and maternal-fetal medicine.

Key Points: 
  • Mirvie , a company pioneering the prediction of life-threatening pregnancy complications months in advance, today announced the completion of enrollment of its landmark 10,000 person research study for pregnancy health, in collaboration with leading experts in obstetrics and maternal-fetal medicine.
  • “This monumental effort represents a new chapter for pregnancy health,” said Maneesh Jain, CEO and co-founder of Mirvie.
  • “Today, we face a massive crisis in maternal health, and innovative solutions are desperately needed.
  • The audacious scale of this generalizable study – involving over 10,000 individuals – creates the largest and richest biobank of pregnancy transcriptomes ever to exist.”
    Led by internationally renowned experts in pregnancy health, the U.S.-based study seeks to understand how RNA messages found in expectant mothers’ blood can predict life-threatening pregnancy complications.

The Inner Circle Acknowledges, Nana E. Tchabo, MD, FACOG as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology

Retrieved on: 
Monday, November 13, 2023

CHESTER, N.J., Nov. 13, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Nana E. Tchabo, MD, FACOG, is acknowledged as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology.

Key Points: 
  • CHESTER, N.J., Nov. 13, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Nana E. Tchabo, MD, FACOG, is acknowledged as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology.
  • Dr. Tchabo pursued higher education at Brown University where she received a Bachelor of Science in Neuroscience, minoring in Women's Studies.
  • She then attended the Warren Alpert Medical School of Brown University for her medical degree, where she was cited for academic excellence.
  • Dr. Tchabo currently works at Atlantic Women's Cancer Associates, a part of Atlantic Health Systems Morristown and Overlook Medical Centers.

Predictive Oncology Completes AI-driven Study of Ovarian Cancer with UPMC Magee-Womens Hospital

Retrieved on: 
Wednesday, November 8, 2023

PITTSBURGH, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, announced today that it has completed a multi-year study with UPMC Magee-Womens Hospital.

Key Points: 
  • PITTSBURGH, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, announced today that it has completed a multi-year study with UPMC Magee-Womens Hospital.
  • The objective of the study was to evaluate the use of AI to build multi-omic machine learning (ML) models and test if these models can learn associations between the datasets and ovarian cancer patient short- and long-term survival.
  • “This study incorporated one of the largest sets of multi-omic data from 235 ovarian cancer patients, to identify the key features from these datasets driving overall survival endpoints.
  • “Our collaboration with Predictive Oncology brought cutting-edge AI capabilities, using multi-omic features to deliver strong predictive models with high levels of accuracy.

Study Reveals the Need to Expand Maternal Mortality Categorization Beyond Pregnancy-Related Deaths

Retrieved on: 
Wednesday, October 25, 2023

BOSTON, Oct. 25, 2023 /PRNewswire-PRWeb/ -- The Center for Black Maternal Health and Reproductive Justice announced today its participation in a new study that revealed pregnancy-associated deaths as an urgent public health concern deserving greater scrutiny by maternal mortality review committees and the clinical and public health community at large. Research has found severe maternal morbidity (SMM), opioid use disorder, and prior hospital contacts were contributors to pregnancy-associated, but not pregnancy-related deaths in Massachusetts from 2002 to 2019. It also identified four times as many pregnancy-associated deaths than pregnancy-related ones and a high rate of hospital contacts (hospital admission, observational stays, and ER visits) for those who ultimately died during pregnancy through one year postpartum.

Key Points: 
  • New Research Shows Prior Hospitalization, Severe Maternal Morbidity, and Opioid Use Disorder Were Key Contributors to Pregnancy-Associated Deaths in Massachusetts from 2002 to 2019.
  • BOSTON, Oct. 25, 2023 /PRNewswire-PRWeb/ -- The Center for Black Maternal Health and Reproductive Justice announced today its participation in a new study that revealed pregnancy-associated deaths as an urgent public health concern deserving greater scrutiny by maternal mortality review committees and the clinical and public health community at large.
  • Research has found severe maternal morbidity (SMM), opioid use disorder, and prior hospital contacts were contributors to pregnancy-associated, but not pregnancy-related deaths in Massachusetts from 2002 to 2019.
  • There is a clear need to expand the focus of maternal mortality to the much larger group of pregnancy-associated deaths to understand the risk factors and events that lead to many of these preventable deaths."

Lupus Foundation of America Awards Five Summer Fellowship Grants to Young Scientists, Supporting Growth of Lupus Research Field

Retrieved on: 
Monday, July 31, 2023

This program supports mentored research experiences for outstanding undergraduate, graduate and medical students conducting lupus research.

Key Points: 
  • This program supports mentored research experiences for outstanding undergraduate, graduate and medical students conducting lupus research.
  • The program's focus on young scientists is important for cultivating future lupus researchers and growth in the next generation.
  • "The Lupus Foundation of America's Gina M. Finzi Memorial Student Fellowship Program shows our investment in the future minds that will transform lupus research.
  • The research conducted by the awardees will contribute to a wide range of important areas within lupus research:

Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer

Retrieved on: 
Wednesday, May 24, 2023

SALT LAKE CITY, May 24, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the addition of Folate Receptor Alpha (FRα) to its Precise™ Oncology Solutions portfolio. The new biomarker adds another companion diagnostic option for providers to help guide treatment decisions for patients with ovarian cancer.

Key Points: 
  • SALT LAKE CITY, May 24, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the addition of Folate Receptor Alpha (FRα) to its Precise™ Oncology Solutions portfolio.
  • The new biomarker adds another companion diagnostic option for providers to help guide treatment decisions for patients with ovarian cancer.
  • FRα is a biomarker commonly expressed in patients with ovarian cancer.
  • FRα is a newly recommended biomarker test included in the National Comprehensive Cancer Network treatment guidelines for ovarian cancer.

ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

Retrieved on: 
Thursday, May 11, 2023

SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the first quarter ended March 31, 2023 and provided clinical development and operational highlights.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the first quarter ended March 31, 2023 and provided clinical development and operational highlights.
  • “In the first quarter of 2023, we continued to make significant progress in advancing our lead program, evorpacept, through new collaborations and clinical trial starts,” said Dr. Jaume Pons, Founder, President and Chief Executive Officer of ALX Oncology.
  • First Quarter 2023 Financial Results:
    Cash, Cash Equivalents and Investments: Cash, cash equivalents and investments as of March 31, 2023 were $256.2 million.
  • A reconciliation of GAAP to non-GAAP financial results can be found at the end of this press release.